Solid lipid nanoparticle

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Retrieved on: 
Thursday, February 15, 2024
PCSK9, Toxicity, Pathology, Moyamoya disease, CAPE, Stroke, Life, Antibody, Risk, Safety, Lipid, Journal, Apolipoprotein, Heart, Atherosclerosis, LDLR, Hypercholesterolemia, Solid lipid nanoparticle, Immune system, Pharmaceutical industry

CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024).

Key Points: 
  • Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
  • The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024).
  • “Vaxxinity is committed to providing scalable, accessible, game-changing solution for worldwide heart health,” said Mei Mei Hu, CEO of Vaxxinity.
  • A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.

Informatics Solutions for LNP

Retrieved on: 
Thursday, September 28, 2023
Data management, Informatics, Zeta, ELN, Lipid, Research, Messenger, Small RNA, PDI, Oligonucleotide, Solid lipid nanoparticle, Nursing, LNP

CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Scilligence, a leading innovator of scientific software solutions, has developed Lipid Nanoparticle (LNP)-specific informatics solutions to address a critical unmet need for developing new drug modalities including oligonucleotides such as siRNA and mRNA. Scientists will be able to use Scilligence RegMol and Scilligence ELN to capture and share R&D data regarding LNP work for therapeutics delivery.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Scilligence , a leading innovator of scientific software solutions, has developed Lipid Nanoparticle (LNP)-specific informatics solutions to address a critical unmet need for developing new drug modalities including oligonucleotides such as siRNA and mRNA.
  • These LNP-specific informatics solutions will help researchers optimize experiments, identify trends, and accelerate the development of new LNP-based therapies.
  • "It's not trivial to develop LNP-specific informatics solutions that require a technology foundation capable of supporting a wide variety of modalities, including oligonucleotides and lipids.
  • For more information about Sciligence's LNP informatics solutions and how it can transform your research and data management processes, please visit www.scilligence.com .

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023
Biochemistry, Business development, Drug development, University, Drug delivery, Organic chemistry, Approved Drug Products with Therapeutic Equivalence Evaluations, Institute of technology, Biotechnology, Lipid, MBA, OSD, Technical University of Berlin, RNA, University of Bonn, University of Graz, CDMO, Professor, Machine learning, Pharmaceutics, Knowledge, Growth, AI, API, LNP, Solid lipid nanoparticle, Oligonucleotide, Bipolar Integrated Technology, Pharmacology, Peptide, Fine chemical, Vaccine, Management, Biopharmaceutical, Chemistry, Ludwig Maximilian University of Munich

CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.

Key Points: 
  • CDMO CordenPharma establishes world-class Technology & Science Advisory Board of experts across 6 technology platforms.
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.

CordenPharma Establishes World-Class Technology & Science Advisory Board of Experts Across Six Technology Platforms

Retrieved on: 
Wednesday, July 26, 2023
Biochemistry, Business development, Drug development, University, Drug delivery, Organic chemistry, Approved Drug Products with Therapeutic Equivalence Evaluations, Institute of technology, Biotechnology, Lipid, MBA, OSD, Technical University of Berlin, RNA, University of Bonn, University of Graz, CDMO, Professor, Machine learning, Pharmaceutics, Knowledge, Growth, AI, API, LNP, Solid lipid nanoparticle, Oligonucleotide, Bipolar Integrated Technology, Pharmacology, Peptide, Fine chemical, Management, Biopharmaceutical, Chemistry, Ludwig Maximilian University of Munich

The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.

Key Points: 
  • The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries.
  • CordenPharma's TSAB brings together eight scientific experts from various disciplines, including chemistry, pharmacology, biotechnology, and regulatory affairs.
  • Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms .
  • Dr. Michael Quirmbach, CEO & President at CordenPharma, said: "CordenPharma is honored to have the opportunity to work with these distinguished scientific experts.

Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets

Retrieved on: 
Monday, June 26, 2023
GMP, Solid lipid nanoparticle, Cannabinoid, FSE, Absorption, Capsule, TSX, Administration, Fine chemical

TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce the extension of its existing strategic manufacturing agreement with Medipharm Labs Inc. (“MediPharm”) for the commercialization of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (“SEDDS”) technology capsules for the Canadian and international markets.

Key Points: 
  • Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary SEDDS technology capsules across Canadian adult use, medical and international channels.
  • Under the expanded Strategic Manufacturing Agreement, Avicanna intends to commercialize its proprietary SEDDS technology capsules, under the RHO Phyto brand, across domestic nation-wide medical channels including the Avicanna’s MyMedi.ca online cannabis care platform and MediPharm’s Canna farms platform.
  • Additionally, MediPharm intends to commercialize the capsules across adult use wellness channels under its MediPharm Labs brand.
  • MediPharm intends to manufacture these proprietary capsules in accordance with GMP standards to fulfill domestic and international pharmaceutical standards.

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, Solid lipid nanoparticle, RNA, SaRNA, Development, Emergent, CMO, CMOS, BioNTech, MicroRNA, LNP, Plasmid, Merck, Diosynth, CGMP, Nucleic acid, Organization, Clinical trial, Research, Operation Warp Speed, Oncology, PTS, Merck Group, COVID-19, Commercial, AMRI, CDMO, Safety, CAGR, Technology, Viral Research and Diagnostic Laboratories, Vaccine, SM-102, Partnership, LPN, International, Nanoparticle, Prevalence, Contract, Drug development, FDB, Industry, Attention, Fine chemical, Pharmaceutical industry, Others

According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles (LNPs) CDMO services in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA, Emergent, Nucleic acid, Organization, Research, COVID-19, LNP, SM-102, LPN, Drug development, Solid lipid nanoparticle, Development, Plasmid, Merck, Partnership, PTS, Oncology, Merck Group, Commercial, Safety, Technology, Viral Research and Diagnostic Laboratories, International, Nanoparticle, Prevalence, SaRNA, CMO, CMOS, BioNTech, MicroRNA, Diosynth, Clinical trial, AMRI, CDMO, Attention, RNA transfection, CGMP, Operation Warp Speed, Vaccine, Contract, FDB, Industry, Fine chemical, Pharmaceutical industry, Others

This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.

Key Points: 
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Lipid nanoparticles provide the prospect of developing new therapies due to their unique size dependent features.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Retrieved on: 
Tuesday, February 15, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Overload, ICU, Patient, CEO, EUA, Research institute, Risk, Department, Death, Mortal Kombat, Safety, Standard of care, Cystic fibrosis, MD, Solid lipid nanoparticle, FDA, Population, Fenretinide, Disease, Anne Arundel Medical Center, Delta, Inflammation, Hospital, Severe acute respiratory syndrome coronavirus 2, COVID-19, Pharmaceutical industry, Vaccine, LAU-7b, RESOLUTION Phase 2/3 clinical trial, Laurent Pharmaceuticals, LAU-7B, RESOLUTION PHASE 2/3 CLINICAL TRIAL, LAURENT PHARMACEUTICALS

There is still an important treatment gap for moderate-to-severe COVID-19 patients, the population most at-risk of progressing to respiratory failure, said Radu Pislariu, MD, President and CEO of Laurent Pharmaceuticals.

Key Points: 
  • There is still an important treatment gap for moderate-to-severe COVID-19 patients, the population most at-risk of progressing to respiratory failure, said Radu Pislariu, MD, President and CEO of Laurent Pharmaceuticals.
  • LAU-7b is developed as a broadly effective oral COVID-19 therapeutic targeting host cells membrane lipids to exert dual antiviral and inflammation-controlling activity.
  • RESOLUTION is a placebo-controlled Phase 2/3 study of oral LAU-7b, administered once-a-day for 14 days on top of standard of care, in hospitalized COVID-19 patients at risk of developing pulmonary complications.
  • Laurent Pharmaceuticals is a clinical stage biotech company focusing on the modulation of cell membrane lipids for addressing life-threatening diseases.

Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death

Retrieved on: 
Wednesday, December 15, 2021
Medical Devices, General Health, Infectious Diseases, Hospitals, Science, Genetics, Fitness & Nutrition, Nursing, Medical Supplies, Clinical Trials, FDA, Biotechnology, Alternative Medicine, Health, Research, Other Health, Pharmaceutical, Standard of care, Food, Solution, Ambulatory care, FDA, Government, Metabolism, Innovation, Death, COVID-19 testing, Solid lipid nanoparticle, Severe acute respiratory syndrome coronavirus 2, Adult, Cystic fibrosis, NRC, COVID-19, National Research Council Canada, Economic development, Fenretinide, Risk, EUA, CEO, Hospital, Safety, Inflammation, Patient, Mortality, Disease, Quality of life, National Research Council, Delta, Overalls, MD, IRAP, Pharmaceutical industry, LAU-7b, Laurent Pharmaceuticals, LAU-7B, LAURENT PHARMACEUTICALS

The study drug was administered for 14 days on top of standard of care.

Key Points: 
  • The study drug was administered for 14 days on top of standard of care.
  • LAU-7b was well-tolerated, with a safety profile comparable to the placebo arm and consistent with the existing safety data.
  • Moreover, its convenient once-a-day oral administration allows for flexible use during hospitalization, as well as an at-home treatment after discharge, added Dr Pislariu.
  • Existing data suggest that low-dose fenretinide has the potential to modulate certain membrane lipids and exerts antiviral, inflammatory-controlling, and antifibrotic properties.